This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Phase IIb Study to Study the Efficacy of AT1001 to Treat Celiac Disease

This study has been completed.
Information provided by:
Alba Therapeutics Identifier:
First received: June 25, 2007
Last updated: January 18, 2010
Last verified: January 2010

This study will look at 3 doses of AT1001 for efficacy and safety for the treatment of celiac disease.

The primary efficacy outcome is to evaluate the efficacy of multiple dose levels of AT-1001 in preventing intestinal permeability changes induced by a 6- week gluten challenge.

Condition Intervention Phase
Celiac Disease Drug: AT-1001 Drug: placebo Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase IIb, Randomized, Double-Blind, Placebo Controlled, Dose Ranging, Multicenter Study to Determine the Safety, Tolerance, and Efficacy of AT-1001 in Celiac Disease Subjects During a Gluten Challenge

Resource links provided by NLM:

Further study details as provided by Alba Therapeutics:

Primary Outcome Measures:
  • To evaluate the efficacy of multiple dose levels of AT-1001 in preventing intestinal permeability changes induced by a 6- week gluten challenge. [ Time Frame: 6 weeks ]

Secondary Outcome Measures:
  • To prospectively validate a composite, weighed index of celiac disease activity [ Time Frame: 6 weeks ]
  • Monitoring of adverse events (AEs) including signs and symptoms of gluten toxicity, Vital signs, Physical exam findings, EKG, Pregnancy Screening, Clinical laboratory testing of chemistry, hematology, and urinalysis specimens [ Time Frame: 6 weeks ]

Enrollment: 184
Study Start Date: August 2007
Study Completion Date: March 2009
Primary Completion Date: October 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
AT-1001 capsules 1 mg with 900mg gluten
Drug: AT-1001
capsules, TID
Experimental: 2
AT-1001 capsules 4 mg with 900 mg gluten
Drug: AT-1001
capsules, TID
Experimental: 3
AT-1001 capsules 8 mg with 900 mg gluten
Drug: AT-1001
capsules, TID
Placebo Comparator: 4
Drug placebo capsules with 900 mg gluten
Drug: placebo
capsules, TID

Detailed Description:
This is an outpatient, randomized, double blind multicenter study. Subjects will remain on their gluten-free diet throughout the duration of the trial. Study drug or drug placebo capsules will be administered TID 15 minutes before each meal (breakfast, lunch, and dinner). Gluten or gluten placebo capsules will be taken TID with each meal.

Ages Eligible for Study:   18 Years to 72 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

Eligible subjects must meet all of the following criteria before being enrolled into the study:

  1. Age between 18 and 72 years, inclusive.
  2. Diagnosed with celiac disease for more than 6 months.
  3. Anti-Tissue Transglutaminase (anti-tTG) less than 10 EU.
  4. On a gluten-free diet for at least 6 months.
  5. BMI between 18.5 and 38, inclusive.

Exclusion Criteria

Subjects meeting any one of the following criteria are not eligible for the study:

  1. Current smoker.
  2. Has chronic active GI disease other than celiac disease (e.g. Crohn's, Colitis).
  3. Has diabetes (Type 1 or Type 2).
  4. Unable to abstain from alcohol consumption for 48 hours prior to each intestinal permeability collection throughout the study.
  5. Unable to refrain from consuming non-steroidal anti-inflammatory agents, including aspirin ("NSAIDs") for 48 hours prior to each intestinal permeability collection throughout the study.
  6. Participated in any clinical drug study within the past 30 days or has had previous exposure to AT-1001.
  7. Presents with or has a history of dermatitis herpetiformis.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00492960

  Hide Study Locations
United States, Arizona
Study Site
Scottsdale, Arizona, United States, 85259
United States, Colorado
Study Site
Colorado Springs, Colorado, United States, 80907
United States, Illinois
Study Site
Chicago, Illinois, United States, 60637
United States, Kentucky
Study Site
Lexington, Kentucky, United States, 40536
United States, Maryland
Study Site
Hagerstown, Maryland, United States, 21740
United States, Massachusetts
Study Site
Boston, Massachusetts, United States, 02215
United States, Michigan
Study Site
Troy, Michigan, United States, 48084
United States, Minnesota
Study Site
Rochester, Minnesota, United States, 55905
United States, New York
Study Site
New York, New York, United States, 10032
United States, North Carolina
Study Site
Asheville, North Carolina, United States, 28801
United States, Ohio
Study Site
Cleveland, Ohio, United States, 44195
United States, Pennsylvania
Study Site
Philadelphia, Pennsylvania, United States, 19107
Study Site
Pittsburgh, Pennsylvania, United States, 15243
United States, Texas
Study Site
Houston, Texas, United States, 77030
Study Site
Plano, Texas, United States, 75093
United States, Virginia
Study Site
Richmond, Virginia, United States, 23298
United States, Washington
Study Site
Seattle, Washington, United States, 98101
Canada, Alberta
Study Site
Edmonton, Alberta, Canada
Canada, British Columbia
Study Site
Kelowna, British Columbia, Canada
Study Site
Calgary, Canada
Study Site
Montreal, Canada
Study Site
Toronto, Canada
Study Site
Winnipeg, Canada
Sponsors and Collaborators
Alba Therapeutics
Study Director: Francisco Leon, MD, Ph.D. Alba Therapeutics Corp
  More Information

Additional Information:
Responsible Party: Francisco Leon, Executive Director of Medical Affairs, Alba Therapeutics Identifier: NCT00492960     History of Changes
Other Study ID Numbers: CLIN1001-006
Study First Received: June 25, 2007
Last Updated: January 18, 2010

Keywords provided by Alba Therapeutics:
Celiac Disease

Additional relevant MeSH terms:
Celiac Disease
Malabsorption Syndromes
Intestinal Diseases
Gastrointestinal Diseases
Digestive System Diseases
Metabolic Diseases processed this record on August 17, 2017